Scribe Raises $128.7M in Upsized IPO Backed by Eli Lilly
Scribe Therapeutics raised $128.7 million in an upsized IPO, pricing above the initial range. Strong institutional demand and the backing of Eli Lilly lifted the stock in early trading, reflecting bullish sentiment for the newly public biotech.
- ▲ Upsized IPO with shares priced above the high end of the marketed range
- ▲ Validation from Eli Lilly as a major strategic investor
- ▼ Post-IPO lockup expiration could trigger insider selling pressure
- ▼ Broader biotech sector rotation away from high-risk early-stage names
▼ Show FAQ (2) ▲ Hide FAQ
Why did Scribe's IPO see upside demand?
Investors were attracted to Scribe's gene editing platform and its partnership with Eli Lilly, which de-risks the pipeline and provides near-term collaboration revenue. The upsizing from the initial range reflects that demand exceeded the offering size, leading to a higher deal price and larger proceeds.
How might Scribe's stock perform after the IPO?
In the short term, post-IPO momentum could continue if lock-up agreements support a tight float and sentiment remains positive. However, typical biotech volatility and the lack of near-term catalysts beyond the IPO itself may limit further gains until clinical milestones are reached.